SMP 028
Alternative Names: SMP-028Latest Information Update: 22 Jul 2023
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Dainippon Sumitomo Pharma; Sumitomo Pharma; Sumitomo Pharma America
- Class Antiasthmatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 03 Feb 2011 Discontinued - Phase-I for Allergic rhinitis in United Kingdom (PO)
- 03 Feb 2011 Discontinued - Phase-I for Asthma in Japan (PO)
- 03 Feb 2011 Discontinued - Phase-I for Asthma in Netherlands (PO)